[Expression of thrombogenic substances by neoplasms: TF and cancer procoagulant. Pathogenic effects].
The paper reviews the current studies on mechanism of thrombo-embolic complications in patients with malignancy. The neoplastic cells can express procoagulants like tissue factor (TF), cancer procoagulant (CP) and others, which induce thrombin formation in blood plasma and cause thrombo-embolic events, disseminated intravascular coagulation and other complications. Both procoagulants are acting via extrinsic pathway--TF makes complexes with factor VII and calcium ions, while CP acts directly on factor X transforming it into active form (Xa). Gynecological tumor-related complications occur in 20-30% patients with ovarian or uterine cancer.
Uszyński
M
M
Katedry i Zakładu Propedeutyki Medycyny Akademii Medycznej w Bydgoszczy.
D000970:Antineoplastic Agents / Q000009:adverse effects; D005260:Female; D006801:Humans; D009369:Neoplasms / Q000150:complications* / Q000378:metabolism*; D010051:Ovarian Neoplasms / Q000150:complications; D013923:Thromboembolism / Q000209:etiology*; D013925:Thromboplastin / Q000378:metabolism*; D014594:Uterine Neoplasms / Q000150:complications
D000970:Antineoplastic Agents; D013925:Thromboplastin